Neumora Therapeutics IncNASDAQ:NMRA
- LAST PRICE14.7600
- TODAY'S CHANGE (%)1.2150 (8.9701%)
- Bid / Lots14.7600/ 10
- Ask / Lots15.0000/ 1
- Open / Previous Close13.7800 / 13.5450
- Day Range
- 52 Week Range
- Volume621,038
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NMRA |
|---|---|---|
| 09:32 ET | 2818 | 13.675 |
| 09:41 ET | 200 | 13.81 |
| 09:45 ET | 100 | 13.81 |
| 09:50 ET | 303 | 13.84 |
| 09:52 ET | 200 | 13.84 |
| 09:54 ET | 338 | 13.83 |
| 09:56 ET | 700 | 13.74 |
| 09:59 ET | 836 | 13.75 |
| 10:01 ET | 3581 | 13.905 |
| 10:03 ET | 2248 | 13.96 |
| 10:06 ET | 25648 | 14.11 |
| 10:08 ET | 2055 | 14.11 |
| 10:10 ET | 13192 | 13.97 |
| 10:12 ET | 3572 | 13.895 |
| 10:14 ET | 5125 | 13.96 |
| 10:15 ET | 3797 | 13.99 |
| 10:17 ET | 599 | 14.02 |
| 10:19 ET | 660 | 13.995 |
| 10:21 ET | 200 | 14.01 |
| 10:24 ET | 3074 | 13.94 |
| 10:26 ET | 100 | 13.9 |
| 10:28 ET | 1070 | 13.8699 |
| 10:30 ET | 1900 | 13.765 |
| 10:32 ET | 400 | 13.775 |
| 10:33 ET | 100 | 13.79 |
| 10:35 ET | 100 | 13.77 |
| 10:37 ET | 506 | 13.747 |
| 10:39 ET | 200 | 13.73 |
| 10:44 ET | 200 | 13.745 |
| 10:46 ET | 2800 | 13.91 |
| 10:48 ET | 362 | 13.935 |
| 10:50 ET | 1620 | 13.93 |
| 10:51 ET | 936 | 14 |
| 10:53 ET | 5050 | 14.15 |
| 10:55 ET | 354 | 14.135 |
| 11:00 ET | 100 | 14.16 |
| 11:02 ET | 1198 | 14.17 |
| 11:06 ET | 100 | 14.13 |
| 11:08 ET | 248 | 14.18 |
| 11:09 ET | 2757 | 14.26 |
| 11:13 ET | 331 | 14.26 |
| 11:15 ET | 537 | 14.26 |
| 11:18 ET | 3339 | 14.19 |
| 11:20 ET | 318 | 14.23 |
| 11:22 ET | 300 | 14.14 |
| 11:24 ET | 500 | 14.13 |
| 11:26 ET | 400 | 14.135 |
| 11:27 ET | 1101 | 14.11 |
| 11:31 ET | 2418 | 14.1 |
| 11:38 ET | 300 | 14.16 |
| 11:40 ET | 1401 | 14.2 |
| 11:42 ET | 600 | 14.215 |
| 11:44 ET | 300 | 14.27 |
| 11:45 ET | 1126 | 14.245 |
| 11:47 ET | 1054 | 14.26 |
| 11:51 ET | 450 | 14.22 |
| 11:56 ET | 300 | 14.25 |
| 11:58 ET | 300 | 14.25 |
| 12:00 ET | 100 | 14.265 |
| 12:03 ET | 16063 | 14.33 |
| 12:05 ET | 100 | 14.335 |
| 12:07 ET | 100 | 14.36 |
| 12:09 ET | 200 | 14.345 |
| 12:12 ET | 900 | 14.37 |
| 12:14 ET | 200 | 14.4 |
| 12:16 ET | 300 | 14.4 |
| 12:18 ET | 840 | 14.4 |
| 12:20 ET | 1529 | 14.44 |
| 12:23 ET | 5808 | 14.39 |
| 12:25 ET | 100 | 14.41 |
| 12:27 ET | 600 | 14.41 |
| 12:30 ET | 100 | 14.41 |
| 12:32 ET | 200 | 14.43 |
| 12:34 ET | 1897 | 14.375 |
| 12:39 ET | 600 | 14.3793 |
| 12:41 ET | 9577 | 14.38 |
| 12:43 ET | 4385 | 14.49 |
| 12:45 ET | 5252 | 14.54 |
| 12:48 ET | 1195 | 14.51 |
| 12:50 ET | 329 | 14.5 |
| 12:52 ET | 4001 | 14.49 |
| 12:54 ET | 15971 | 14.36 |
| 12:56 ET | 4100 | 14.43 |
| 12:57 ET | 155 | 14.4137 |
| 12:59 ET | 2620 | 14.4 |
| 01:01 ET | 200 | 14.38 |
| 01:03 ET | 100 | 14.385 |
| 01:06 ET | 870 | 14.4191 |
| 01:08 ET | 600 | 14.44 |
| 01:10 ET | 1156 | 14.45 |
| 01:12 ET | 100 | 14.44 |
| 01:14 ET | 700 | 14.45 |
| 01:15 ET | 396 | 14.45 |
| 01:17 ET | 100 | 14.435 |
| 01:19 ET | 100 | 14.43 |
| 01:21 ET | 500 | 14.455 |
| 01:24 ET | 1100 | 14.48 |
| 01:28 ET | 1100 | 14.53 |
| 01:30 ET | 1313 | 14.52 |
| 01:32 ET | 450 | 14.51 |
| 01:33 ET | 1300 | 14.58 |
| 01:35 ET | 6042 | 14.54 |
| 01:37 ET | 300 | 14.53 |
| 01:39 ET | 8109 | 14.495 |
| 01:42 ET | 3500 | 14.48 |
| 01:44 ET | 9299 | 14.48 |
| 01:46 ET | 1346 | 14.465 |
| 01:48 ET | 1322 | 14.42 |
| 01:50 ET | 9532 | 14.4 |
| 01:51 ET | 1600 | 14.4 |
| 01:53 ET | 243 | 14.37 |
| 01:55 ET | 100 | 14.345 |
| 01:57 ET | 400 | 14.39 |
| 02:00 ET | 600 | 14.4 |
| 02:04 ET | 200 | 14.4 |
| 02:06 ET | 400 | 14.38 |
| 02:08 ET | 2919 | 14.4 |
| 02:09 ET | 504 | 14.41 |
| 02:13 ET | 200 | 14.44 |
| 02:18 ET | 200 | 14.47 |
| 02:22 ET | 500 | 14.48 |
| 02:24 ET | 100 | 14.495 |
| 02:26 ET | 205 | 14.52 |
| 02:27 ET | 100 | 14.54 |
| 02:29 ET | 2204 | 14.5598 |
| 02:33 ET | 5060 | 14.54 |
| 02:36 ET | 300 | 14.55 |
| 02:38 ET | 1100 | 14.51 |
| 02:40 ET | 1302 | 14.48 |
| 02:42 ET | 455 | 14.5 |
| 02:44 ET | 2007 | 14.49 |
| 02:45 ET | 3405 | 14.51 |
| 02:47 ET | 800 | 14.52 |
| 02:49 ET | 1542 | 14.53 |
| 02:51 ET | 966 | 14.54 |
| 02:54 ET | 2156 | 14.52 |
| 02:56 ET | 700 | 14.52 |
| 02:58 ET | 100 | 14.53 |
| 03:00 ET | 900 | 14.56 |
| 03:02 ET | 1596 | 14.52 |
| 03:05 ET | 3945 | 14.52 |
| 03:07 ET | 1300 | 14.61 |
| 03:09 ET | 2315 | 14.6 |
| 03:12 ET | 600 | 14.56 |
| 03:14 ET | 2100 | 14.6 |
| 03:16 ET | 2260 | 14.67 |
| 03:18 ET | 2222 | 14.65 |
| 03:21 ET | 100 | 14.643757 |
| 03:23 ET | 533 | 14.66 |
| 03:25 ET | 2215 | 14.63 |
| 03:27 ET | 872 | 14.665 |
| 03:30 ET | 465 | 14.69 |
| 03:32 ET | 2450 | 14.67 |
| 03:34 ET | 703 | 14.68 |
| 03:36 ET | 29322 | 14.715 |
| 03:38 ET | 3185 | 14.73 |
| 03:39 ET | 3097 | 14.72 |
| 03:41 ET | 47427 | 14.81 |
| 03:43 ET | 4379 | 14.76 |
| 03:45 ET | 2492 | 14.82 |
| 03:48 ET | 1758 | 14.76 |
| 03:50 ET | 1626 | 14.76 |
| 03:52 ET | 2785 | 14.76 |
| 03:54 ET | 8618 | 14.85 |
| 03:56 ET | 5827 | 14.84 |
| 03:57 ET | 5061 | 14.785 |
| 03:59 ET | 78446 | 14.76 |
Oct 1, 2024
DJ Neumora Therapeutics Initiated at Buy by HC Wainwright & Co., from 6:35AM ET on Tuesday Oct 01, 2024 by Dow Jones
6:35AM ET on Tuesday Oct 01, 2024 by Dow Jones
Sep 12, 2024
DJ Neumora Therapeutics Price Target Maintained With a $23.00/Share by Needham, from 1:41PM ET on Thursday Sep 12, 2024 by Dow Jones
1:41PM ET on Thursday Sep 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neumora Therapeutics Inc | 2.4B | -8.9x | --- |
Immunitybio Inc | 2.4B | -3.7x | --- |
Janux Therapeutics Inc | 2.3B | -49.2x | --- |
Keros Therapeutics Inc | 2.3B | -11.9x | --- |
CG Oncology Inc | 2.5B | -31.4x | --- |
Structure Therapeutics Inc | 2.5B | -19.2x | --- |
Company Information
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Contact Information
- Headquarters
- 490 Arsenal Way, Suite 200WATERTOWN, MA, United States 02472
- Phone
- 857-760-0900
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Co-Founder
- Paul Berns
- President, Chief Executive Officer, Director
- Henry Gosebruch
- Co-Founder, Chief Operating Officer
- Carol Suh
- Chief Financial Officer
- Joshua Pinto
- Chief Strategy Officer
- Daljit Aurora
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 160.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.66 |
Book Value | $2.95 |
P/E Ratio | -8.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
